271 related articles for article (PubMed ID: 20809122)
21. [Inhibition of ABC-transporter(s)' function in non-small cell lung cancer cells by platinum drugs].
Bogush TA; Konukhova AV; Ravcheeva AB; Zabotina TN; Kadagidze ZG; Bogush EA; Komov DV; Polotskiĭ BE; Laktionov KK; Davydov MI
Antibiot Khimioter; 2003; 48(10):11-5. PubMed ID: 15004974
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer.
Eckardt JR; Bentsion DL; Lipatov ON; Polyakov IS; Mackintosh FR; Karlin DA; Baker GS; Breitz HB
J Clin Oncol; 2009 Apr; 27(12):2046-51. PubMed ID: 19289620
[TBL] [Abstract][Full Text] [Related]
23. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
[TBL] [Abstract][Full Text] [Related]
24. The role of platinum uptake and glutathione levels in L1210 cells sensitive and resistant to cisplatin, tetraplatin or carboplatin.
Nicolson MC; Orr RM; O'Neill CF; Harrap KR
Neoplasma; 1992; 39(3):189-95. PubMed ID: 1528325
[TBL] [Abstract][Full Text] [Related]
25. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human cervical cancers.
Monk BJ; Alberts DS; Burger RA; Fanta PT; Hallum AV; Hatch KD; Salmon SE
Gynecol Oncol; 1998 Nov; 71(2):308-12. PubMed ID: 9826477
[TBL] [Abstract][Full Text] [Related]
26. Enhancement of platinum-drug cytotoxicity in a human head and neck squamous cell carcinoma line and its platinum-resistant variant by liposomal amphotericin B and phospholipase A2-II.
Ferguson PJ; Currie C; Vincent MD
Drug Metab Dispos; 1999 Dec; 27(12):1399-405. PubMed ID: 10570020
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin.
Fukuda M; Ohe Y; Kanzawa F; Oka M; Hara K; Saijo N
Anticancer Res; 1995; 15(2):393-8. PubMed ID: 7763011
[TBL] [Abstract][Full Text] [Related]
28. In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473.
Holford J; Sharp SY; Murrer BA; Abrams M; Kelland LR
Br J Cancer; 1998; 77(3):366-73. PubMed ID: 9472630
[TBL] [Abstract][Full Text] [Related]
29. Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines.
Harstrick A; Bokemeyer C; Scharnofkse M; Hapke G; Reile D; Schmoll HJ
Cancer Chemother Pharmacol; 1993; 33(1):43-7. PubMed ID: 8269588
[TBL] [Abstract][Full Text] [Related]
30. Antitumor activity of platinum analogs against human lung cancer cell lines and tumor specimens.
Yonei T; Ohnoshi T; Hiraki S; Ueoka H; Kiura K; Moritaka T; Shibayama T; Tabata M; Segawa Y; Takigawa N
Acta Med Okayama; 1993 Aug; 47(4):233-41. PubMed ID: 8213217
[TBL] [Abstract][Full Text] [Related]
31. In vitro cytotoxicity of novel platinum-based drugs and dichloroacetate against lung carcinoid cell lines.
Fiebiger W; Olszewski U; Ulsperger E; Geissler K; Hamilton G
Clin Transl Oncol; 2011 Jan; 13(1):43-9. PubMed ID: 21239354
[TBL] [Abstract][Full Text] [Related]
32. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds.
Meijer C; Mulder NH; Timmer-Bosscha H; Sluiter WJ; Meersma GJ; de Vries EG
Cancer Res; 1992 Dec; 52(24):6885-9. PubMed ID: 1458477
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
Jain N; Lam YM; Pym J; Campling BG
Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
[TBL] [Abstract][Full Text] [Related]
34. Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs.
Howell SB; Safaei R; Larson CA; Sailor MJ
Mol Pharmacol; 2010 Jun; 77(6):887-94. PubMed ID: 20159940
[TBL] [Abstract][Full Text] [Related]
35. Aberrant expression of TMEM205 signaling promotes platinum resistance in ovarian cancer: An implication for the antitumor potential of DAP compound.
Calo CA; Smith BQ; Dorayappan KDP; Saini U; Lightfoot M; Wagner V; Kalaiyarasan D; Cosgrove C; Wang QE; Maxwell GL; Kálai T; Kuppusamy P; Cohn DE; Selvendiran K
Gynecol Oncol; 2022 Jan; 164(1):136-145. PubMed ID: 34756749
[TBL] [Abstract][Full Text] [Related]
36. Cross-resistance of platinum derivatives in H-1R, a cisplatin-resistant cell line.
Negoro K; Yamano Y; Nakashima D; Saito K; Nakatani K; Shiiba M; Bukawa H; Yokoe H; Uzawa K; Wada T; Tanzawa H; Fujita S
Oncol Rep; 2009 Feb; 21(2):443-9. PubMed ID: 19148521
[TBL] [Abstract][Full Text] [Related]
37. Reduced drug accumulation is more important in acquired resistance against oxaliplatin than against cisplatin in isogenic colon cancer cells.
Ekblad L; Kjellström J; Johnsson A
Anticancer Drugs; 2010 Jun; 21(5):523-31. PubMed ID: 20168208
[TBL] [Abstract][Full Text] [Related]
38. Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells.
Garmann D; Warnecke A; Kalayda GV; Kratz F; Jaehde U
J Control Release; 2008 Oct; 131(2):100-6. PubMed ID: 18691617
[TBL] [Abstract][Full Text] [Related]
39. [Pharmacology of platinum compounds: differences between the three molecules and factors of interpatient variability].
Chatelut E
Bull Cancer; 2011 Nov; 98(11):1253-61. PubMed ID: 22024542
[TBL] [Abstract][Full Text] [Related]
40. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells.
Song IS; Savaraj N; Siddik ZH; Liu P; Wei Y; Wu CJ; Kuo MT
Mol Cancer Ther; 2004 Dec; 3(12):1543-9. PubMed ID: 15634647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
